Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Given Consensus Recommendation of “Hold” by Brokerages

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been assigned a consensus rating of “Hold” from the twenty ratings firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $164.50.

ALNY has been the subject of several recent analyst reports. Citigroup cut Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and raised their target price for the stock from $170.00 to $175.00 in a research note on Friday, February 12th. Piper Sandler boosted their price objective on Alnylam Pharmaceuticals from $169.00 to $181.00 and gave the company an “overweight” rating in a report on Thursday, December 17th. Needham & Company LLC boosted their price objective on Alnylam Pharmaceuticals from $160.00 to $180.00 and gave the company a “buy” rating in a report on Friday, February 12th. BMO Capital Markets downgraded Alnylam Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.00 price objective on the stock. in a report on Monday, January 25th. Finally, Royal Bank of Canada reiterated a “hold” rating on shares of Alnylam Pharmaceuticals in a report on Sunday, February 14th.

ALNY stock traded up $1.52 during midday trading on Thursday, hitting $142.19. 8,323 shares of the company’s stock were exchanged, compared to its average volume of 698,316. The business has a 50-day simple moving average of $143.88 and a two-hundred day simple moving average of $141.81. The stock has a market capitalization of $16.64 billion, a PE ratio of -17.97 and a beta of 1.47. Alnylam Pharmaceuticals has a 1-year low of $103.65 and a 1-year high of $178.41.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Wednesday, February 10th. The biopharmaceutical company reported ($2.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.76) by ($0.33). The business had revenue of $163.56 million for the quarter, compared to analyst estimates of $142.49 million. Alnylam Pharmaceuticals had a negative return on equity of 65.96% and a negative net margin of 222.19%. During the same period last year, the business earned ($2.47) EPS. Equities research analysts forecast that Alnylam Pharmaceuticals will post -7.32 earnings per share for the current fiscal year.

In other news, COO Yvonne Greenstreet sold 3,125 shares of the firm’s stock in a transaction that occurred on Tuesday, January 12th. The shares were sold at an average price of $161.00, for a total transaction of $503,125.00. Following the transaction, the chief operating officer now directly owns 7,945 shares in the company, valued at $1,279,145. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Laurie Keating sold 14,941 shares of the firm’s stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $160.20, for a total transaction of $2,393,548.20. Following the transaction, the executive vice president now owns 2,234 shares in the company, valued at $357,886.80. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

A number of large investors have recently bought and sold shares of the stock. World Asset Management Inc grew its position in Alnylam Pharmaceuticals by 3.1% in the 4th quarter. World Asset Management Inc now owns 2,141 shares of the biopharmaceutical company’s stock valued at $278,000 after buying an additional 65 shares during the last quarter. Gateway Investment Advisers LLC boosted its position in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Gateway Investment Advisers LLC now owns 4,234 shares of the biopharmaceutical company’s stock worth $550,000 after purchasing an additional 77 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in shares of Alnylam Pharmaceuticals by 0.4% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 25,980 shares of the biopharmaceutical company’s stock worth $3,377,000 after purchasing an additional 102 shares in the last quarter. Xponance Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.0% during the 4th quarter. Xponance Inc. now owns 12,079 shares of the biopharmaceutical company’s stock worth $1,570,000 after purchasing an additional 114 shares in the last quarter. Finally, US Bancorp DE boosted its position in shares of Alnylam Pharmaceuticals by 10.7% during the 3rd quarter. US Bancorp DE now owns 1,234 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 92.35% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.

Featured Article: Cryptocurrencies

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.